MEFENAMIC 100MG + PARACETAMOL 250MG/5ML is a dual-active oral liquid formulation designed around accurate concentration, controlled dispersion, uniformity, palatability-related formulation considerations, and physical stability. The specified concentration of each active ingredient requires a carefully developed liquid system capable of maintaining consistent composition throughout manufacturing, filling, storage, and handling. For pharmaceutical companies developing a diversified liquid product range, this formulation can be incorporated into a structured PCD Pharma Franchise portfolio supported by appropriate manufacturing documentation and quality procedures.
Development of this type of formulation requires evaluation of the physicochemical properties of both active ingredients. Solubility, particle size, density, wetting behavior, sedimentation characteristics, viscosity, pH, and compatibility with excipients are considered while establishing the formulation. The final manufacturing process is then designed around the selected formulation technology.
The formulation development of MEFENAMIC 100MG + PARACETAMOL 250MG/5ML begins with defining the concentration of both active ingredients within the specified liquid volume. Because two active components are incorporated into the same dosage form, their individual properties and their interaction with the selected vehicle need to be considered together.
Depending on their physical characteristics and the final formulation design, suitable suspending or solubilizing systems may be incorporated. Other functional ingredients can include wetting agents, viscosity modifiers, sweeteners, flavours, buffers, preservatives, or stabilizing components where appropriate.
The liquid vehicle is designed to provide a suitable balance between physical stability and practical handling. Its rheological characteristics can influence sedimentation, pouring behavior, filling efficiency, and redispersibility.
During development, laboratory-scale trials can be used to determine suitable ingredient concentrations and processing parameters before the formulation is transferred to larger manufacturing batches.
For an oral suspension containing dispersed active ingredients, particle characteristics have a direct influence on product uniformity. Particle-size distribution, surface characteristics, density, and wetting behavior can affect how efficiently the active materials become incorporated into the liquid vehicle.
Where necessary, particle-size reduction or sieving can be used as part of the material-preparation stage. Wetting agents may assist in reducing floating, clumping, or incomplete dispersion of hydrophobic materials. The sequence of addition is also established during formulation development to promote consistent distribution.
The suspension system may be prepared by controlled hydration or dispersion of suitable suspending materials followed by gradual incorporation of the active ingredients. Mixing conditions are selected according to the batch size and formulation characteristics.
Homogenization or controlled agitation may be used to achieve the required distribution throughout the bulk. Sampling at different points of the manufacturing vessel can provide information regarding uniformity before the product proceeds to filling.
A key formulation-development consideration for MEFENAMIC 100MG + PARACETAMOL 250MG/5ML is the relationship between viscosity and sedimentation. The liquid should possess a controlled rheological profile that supports physical stability while remaining suitable for filling and dispensing.
Viscosity measurements can be performed at defined stages of development and production. Changes in viscosity may indicate variations in hydration, mixing, temperature, or ingredient distribution, making this parameter useful for process monitoring.
Sedimentation behavior can also be studied under controlled conditions. The formulation may be evaluated for the rate of settling, sediment characteristics, and ease of redispersion after storage. A well-developed suspension system should demonstrate reproducible behavior when appropriately shaken.
Other physical parameters, including appearance, colour, odour, pH, and homogeneity, can be incorporated into the finished-product specification. These characteristics help maintain a consistent product profile across manufacturing batches.
Manufacturing of the formulation involves controlled preparation of the liquid vehicle, incorporation of active ingredients, mixing, bulk adjustment, and filling. Each step can be performed according to established process parameters and documented operating procedures.
In-process controls may include pH, viscosity, appearance, bulk volume, temperature, mixing time, and suspension uniformity. These checks help identify process variation before the batch reaches final packaging.
Finished-product testing can include identification and assay of both active ingredients, microbial quality, pH, viscosity, physical appearance, dispersibility, fill volume, and other applicable quality attributes.
For aqueous oral formulations, microbiological quality requires particular attention. Pharmaceutical water quality, equipment sanitation, personnel hygiene, environmental controls, and preservation strategy where applicable all contribute to maintaining the required microbiological standard.
Analytical results are reviewed against predefined specifications before batch release. Complete manufacturing and laboratory documentation also supports traceability and reproducibility.
Packaging development for MEFENAMIC 100MG + PARACETAMOL 250MG/5ML involves selecting a bottle and closure system compatible with the liquid formulation. The packaging material should provide suitable protection while maintaining physical and chemical product characteristics throughout the intended storage period.
Bottle material, closure fit, leakage resistance, headspace, fill volume, and product-contact compatibility may be assessed during packaging development. Where necessary, suitable light or moisture protection can also be considered according to the stability characteristics of the formulation.
Stability studies can monitor assay, appearance, pH, viscosity, microbial quality, sedimentation behavior, redispersibility, and other relevant attributes at predetermined intervals. The resulting data can support appropriate storage conditions and shelf-life specifications.
Final packaging checks include fill quantity, closure integrity, labeling, batch coding, manufacturing details, expiry information, and overall pack presentation.
For pharmaceutical companies expanding their oral-liquid portfolio, MEFENAMIC 100MG + PARACETAMOL 250MG/5ML can be integrated into a structured PCD Pharma Franchise range through controlled formulation development, reproducible processing, analytical testing, stability assessment, and suitable packaging. This systematic approach helps establish consistent quality and professional product presentation across the pharmaceutical portfolio.
Mefenamic 100MG + Paracetamol 250MG/5ML with formulation development, manufacturing, quality testing, stability, packaging and PCD Pharma details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech